DGMD Medical

DGMD Medical is a pre-clinical stage biotechnology company dedicated to the discovery and development of novel therapeutics for rare genetic muscle disorders, including Duchenne Muscular Dystrophy (DMD) and Limb-Girdle Muscular Dystrophy (LGMD). The company was founded by Dr. David Glass, a prominent scientist in the field of muscle biology who previously held senior leadership roles at Regeneron and Novartis. DGMD Medical utilizes a deep understanding of the molecular mechanisms governing muscle mass, atrophy, and regeneration to identify and validate high-impact targets. By focusing on the underlying biology of muscle wasting, the company aims to develop treatments that can significantly improve the quality of life and physical function for patients with progressive neuromuscular diseases. Headquartered in Cambridge, Massachusetts, DGMD Medical is backed by leading venture capital firms, including ARCH Venture Partners.